Sutro Biopharma (STRO)
(Delayed Data from NSDQ)
$5.01 USD
+0.46 (10.11%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $4.99 -0.02 (-0.40%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Sutro Biopharma, Inc. (STRO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$12.00 | $20.00 | $5.00 | 163.74% |
Price Target
Based on short-term price targets offered by 10 analysts, the average price target for Sutro Biopharma, Inc. comes to $12.00. The forecasts range from a low of $5.00 to a high of $20.00. The average price target represents an increase of 163.74% from the last closing price of $4.55.
Analyst Price Targets (10)
Broker Rating
Sutro Biopharma, Inc. currently has an average brokerage recommendation (ABR) of 1.18 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 1.18 a month ago based on 11 recommendations.
Of the 11 recommendations deriving the current ABR, 10 are Strong Buy, representing 90.91% of all recommendations. A month ago, Strong Buy represented 90.91%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/STRO.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 10 | 10 | 10 | 10 | 10 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.18 | 1.18 | 1.18 | 1.18 | 1.18 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/15/2024 | Cowen & Co. | Tara Bancroft | Strong Buy | Strong Buy |
8/15/2024 | Truist Securities | Asthika S Goonewardene | Strong Buy | Strong Buy |
8/14/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
8/13/2024 | Wedbush Securities | David M Nierengarten | Strong Buy | Strong Buy |
8/13/2024 | Piper Sandler | Edward A Tenthoff | Strong Buy | Strong Buy |
5/16/2024 | Wells Fargo Securities | Derek C Archila | Hold | Hold |
3/5/2024 | JMP Securities | Reni Benjamin | Strong Buy | Strong Buy |
3/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.18 |
ABR (Last week) | 1.18 |
# of Recs in ABR | 11 |
Average Target Price | $12.00 |
LT Growth Rate | 10.10% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | -0.74 |